For most patient populations treated in outpatient or general ward settings, the results of studies using anti-pneumococcal fluoroquinolones such as levofloxacin as monotherapy have shown them to be equivalent or superior to other regimens. This includes being as effective, or better, than comparator agents such as β-lactams, and macrolides (3). There is retrospective, observational data which suggests that combination therapy is better for patients with severe CAP requiring admission to an ICU (11).